Tags

Type your tag names separated by a space and hit enter

Interstitial lung disease in primary Sjögren's syndrome.
Autoimmun Rev. 2017 Jan; 16(1):48-54.AR

Abstract

Interstitial lung disease (ILD) has been reported in 3 to 11% of patients with primary Sjögren's syndrome (pSS). The aims of this retrospective multicenter study were to: 1) analyze characteristics and outcome of ILD in pSS; and 2) evaluate predictive factors associated with ILD onset and deterioration. Twenty-one of 263 patients with pSS (8%) developed ILD. ILD onset preceded pSS diagnosis (n=5), was concurrently identified in association with pSS (n=6) and developed after pSS onset (n=9). Presenting ILD manifestations were: acute/subacute (n=11) onset of ILD, symptomatic progressive onset of ILD (n=5), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT-scan (n=5). ILD therapy included: steroids (n=21), cyclophosphamide (n=1), azathioprine (n=4) and rituximab (n=1). The course of ILD was as follows: improvement (15.8%), stabilization (47.4%) or deterioration (36.8%). Predictive parameters of ILD onset were: older age (p=0.044), Raynaud's phenomenon (p=0.001) and esophageal involvement (p=0.001). Factors associated with ILD deterioration were: older age (p=0.038) and esophageal involvement (p=0.038). Thus, this study underscores the poor outcome of ILD during pSS; thus, systematic screening of pulmonary involvement is required in pSS patients, resulting in both diagnosis and management at early stage of ILD. We also suggest that patients presenting predictive factors of ILD deterioration may need a closer follow-up and a more aggressive therapy.

Authors+Show Affiliations

Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France.Department of Pneumology, Rouen University Hospital, Rouen, France.Department of Internal Medicine, Amiens University Hospital, Amiens, France.Department of Internal Medicine, Amiens University Hospital, Amiens, France.Department of Internal Medicine, Amiens University Hospital, Amiens, France.Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France.Department of Internal Medicine, Rouen University Hospital, Rouen, France; INSERM U 905, University of Rouen IFRMP, Institute for Biochemical Research, Rouen, France. Electronic address: isabelle.marie@chu-rouen.fr.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

27682894

Citation

Roca, F, et al. "Interstitial Lung Disease in Primary Sjögren's Syndrome." Autoimmunity Reviews, vol. 16, no. 1, 2017, pp. 48-54.
Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev. 2017;16(1):48-54.
Roca, F., Dominique, S., Schmidt, J., Smail, A., Duhaut, P., Lévesque, H., & Marie, I. (2017). Interstitial lung disease in primary Sjögren's syndrome. Autoimmunity Reviews, 16(1), 48-54. https://doi.org/10.1016/j.autrev.2016.09.017
Roca F, et al. Interstitial Lung Disease in Primary Sjögren's Syndrome. Autoimmun Rev. 2017;16(1):48-54. PubMed PMID: 27682894.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interstitial lung disease in primary Sjögren's syndrome. AU - Roca,F, AU - Dominique,S, AU - Schmidt,J, AU - Smail,A, AU - Duhaut,P, AU - Lévesque,H, AU - Marie,I, Y1 - 2016/09/25/ PY - 2016/07/27/received PY - 2016/08/08/accepted PY - 2016/9/30/pubmed PY - 2017/1/17/medline PY - 2016/9/30/entrez KW - Interstitial lung disease KW - Predictive factors KW - Primary Sjögren's syndrome KW - Pulmonary involvement KW - Therapy SP - 48 EP - 54 JF - Autoimmunity reviews JO - Autoimmun Rev VL - 16 IS - 1 N2 - Interstitial lung disease (ILD) has been reported in 3 to 11% of patients with primary Sjögren's syndrome (pSS). The aims of this retrospective multicenter study were to: 1) analyze characteristics and outcome of ILD in pSS; and 2) evaluate predictive factors associated with ILD onset and deterioration. Twenty-one of 263 patients with pSS (8%) developed ILD. ILD onset preceded pSS diagnosis (n=5), was concurrently identified in association with pSS (n=6) and developed after pSS onset (n=9). Presenting ILD manifestations were: acute/subacute (n=11) onset of ILD, symptomatic progressive onset of ILD (n=5), and asymptomatic patients exhibiting abnormalities consistent with ILD on PFTs and HRCT-scan (n=5). ILD therapy included: steroids (n=21), cyclophosphamide (n=1), azathioprine (n=4) and rituximab (n=1). The course of ILD was as follows: improvement (15.8%), stabilization (47.4%) or deterioration (36.8%). Predictive parameters of ILD onset were: older age (p=0.044), Raynaud's phenomenon (p=0.001) and esophageal involvement (p=0.001). Factors associated with ILD deterioration were: older age (p=0.038) and esophageal involvement (p=0.038). Thus, this study underscores the poor outcome of ILD during pSS; thus, systematic screening of pulmonary involvement is required in pSS patients, resulting in both diagnosis and management at early stage of ILD. We also suggest that patients presenting predictive factors of ILD deterioration may need a closer follow-up and a more aggressive therapy. SN - 1873-0183 UR - https://www.unboundmedicine.com/medline/citation/27682894/Interstitial_lung_disease_in_primary_Sjögren's_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1568-9972(16)30212-9 DB - PRIME DP - Unbound Medicine ER -